Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Chris Parker(Royal Marsden NHS Foundation Trust), Oliver Sartor(Mayo Clinic), A. Solberg(San Antonio College), Sophie D. Fosså(Oslo University Hospital), Peter Hoskin(University of Manchester), Nicholas D. James(Royal Marsden NHS Foundation Trust), Øyvind S. Bruland(University of Oslo), J. Garcia‐Vargas(San Antonio College), J. Kliment(Martin University Hospital), David Bottomley(San Antonio College), Joe M. O’Sullivan(San Antonio College), Robert E. Coleman(University of Sheffield), K. Staudacher(San Antonio College), Minghua Shan(San Antonio College), C. Gillies O'Bryan-Tear(San Antonio College), Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada), S. Boehmer(San Antonio College), Marcos F. Dall’Oglio(San Antonio College), Aleš Chodacki(San Antonio College), Isabel Syndikus(San Antonio College), Anders Widmark(Umeå University), Paweł Wiechno(San Antonio College), John Logue(San Antonio College), Daniel Heinrich(San Antonio College), Svein Inge Helle(San Antonio College), Saskia Wedel(Goethe University Frankfurt), Sten Nilsson(San Antonio College), Lars Franzén(San Antonio College), M. Seke(San Antonio College), Dag Clement Johannessen(San Antonio College)
Cited by 3,332
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
|New England Journal of Medicine|2003|2.6k